Ultra-low dose aprotinin decreases transfusion requirements and is cost effective in coronary operations

Annals of Thoracic Surgery

Volumn 71, Issue 1, 2001, Pages 158-164

  Dignan, Rebecca J ^a,b   Law, David W ^a   Seah, Peng W ^a   Manganas, Con W ^a   Newman, David C ^a   Grant, Peter W ^a   Wolfenden, Hugh D ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APROTININ; PLACEBO;

ADULT; AGED; ARTERY GRAFT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEART SURGERY; HUMAN; INTERNAL MAMMARY ARTERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; APROTININ; AUSTRALIA; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; HEMOSTATICS; HUMANS; LOGISTIC MODELS; MIDDLE AGED;

EID: 0035137352     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(00)01860-9     Document Type: Article

References (19)

1. Aprotinin for primary coronary artery bypass grafting: A multicenter trial of three dose regimens
2. Effect of aprotinin on need for blood transfusion after repeat open heart surgery
3. Reduction in costs, blood products, and operating time in patients tmdergoing open heart surgery
4. Effect of aprotinin on need for blood transfusion in patients with septic endocarditis having open-heart surgery
5. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin
6. Hemorrhage and the use of blood products after adult cardiac operations: Myths and realities
7. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations
8. Suppressed fibrinolysis after administration of low-dose aprotinin: Reduced level of plasmin-alpha(2)-plasmin inhibitor complexes and post-operative blood loss
9. Aprotinin: A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery
10. Aprotinin: An update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery
11. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients
12. Effects of minimaldose aprotinin on coronary artery bypass grafting
13. Aprotinin reduces the incidence of stokes following cardiac surgery
14. Re-graft patency and clinical efficacy of aprotinin in elective bypass surgery
15. Aprotinin: Safe and effective only with the full-dose regimen
16. The effect on costs of the use of half-dose aprotinin for first time reoperative coronary artery bypass patients
17. Cost-benefit, and efficacy of aprotinin compared with aminocaproic acid in patients having repeated cardiac operations. A randomized, blinded clinical trial
18. The use of low-dose aprotinin, -aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations
19. High-dose aminocaproic acid versus aprotinin, antifibrinolytics efficacy in first-time coronary operations